VIM and prostate cancer: A recent study has also shown that the LIM domain only 2 (LMO2, a key regulator of hematopoietic stem cell development [264]) is transcriptionally repressed by AR in prostate fibroblasts and that LMO2 is elevated in primary human prostate cancer vimentin+/αSMA+ CAFs in response to enzalutamide treatment [257].